Rakovina Therapeutics Adds Neuro-Oncology Expert to Board
Event summary
- Rakovina Therapeutics appointed Prof. Petra Hamerlik to its board of directors on August 18, 2026.
- Hamerlik, Chair of Translational Neuro-Oncology at the University of Manchester, previously served on Rakovina’s Scientific Advisory Board since November 20, 2023.
- She brings industry experience from AstraZeneca, where she developed brain-penetrant DNA repair inhibitors.
- Rakovina’s board now includes five members, combining academic and industry expertise.
The big picture
Rakovina Therapeutics is bolstering its governance with deep neuro-oncology expertise as it advances AI-powered drug discovery. The appointment of Prof. Petra Hamerlik reflects a strategic focus on brain-penetrant DNA-damage response inhibitors, aligning with broader industry trends toward precision oncology and AI-driven drug development. The move underscores Rakovina’s push to translate its proprietary platforms into clinical candidates, a critical phase for biopharmaceutical startups seeking partnership or acquisition.
What we're watching
- Scientific Leadership
- How Prof. Hamerlik’s academic and industry expertise will shape Rakovina’s brain-penetrant DDR inhibitor programs.
- Clinical Translation
- The pace at which Rakovina advances its three DDR inhibitor programs toward clinical trials.
- Strategic Prioritization
- Whether the combined perspective of Hamerlik and existing board members will sharpen Rakovina’s science prioritization.